Brokerages predict that Diplomat Pharmacy Inc (NYSE:DPLO) will announce earnings of ($0.19) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Diplomat Pharmacy’s earnings, with the lowest EPS estimate coming in at ($0.22) and the highest estimate coming in at ($0.16). Diplomat Pharmacy posted earnings per share of $0.14 in the same quarter last year, which would indicate a negative year-over-year growth rate of 235.7%. The company is expected to issue its next earnings results on Friday, March 20th.
According to Zacks, analysts expect that Diplomat Pharmacy will report full year earnings of ($4.87) per share for the current financial year, with EPS estimates ranging from ($4.90) to ($4.83). For the next financial year, analysts anticipate that the company will report earnings of ($0.62) per share, with EPS estimates ranging from ($1.04) to ($0.39). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Diplomat Pharmacy.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($2.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($2.15). Diplomat Pharmacy had a negative net margin of 12.47% and a negative return on equity of 12.15%. The business had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.17 billion. The company’s revenue was down 5.3% compared to the same quarter last year.
A number of equities analysts have recently issued reports on DPLO shares. ValuEngine downgraded shares of Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 5th. Credit Suisse Group downgraded shares of Diplomat Pharmacy from a “neutral” rating to an “underperform” rating and set a $4.00 target price for the company. in a research note on Thursday. Wells Fargo & Co raised their target price on shares of Diplomat Pharmacy from $3.00 to $4.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 8th. Barclays downgraded shares of Diplomat Pharmacy from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $7.00 to $3.00 in a research note on Wednesday, November 13th. Finally, Zacks Investment Research downgraded shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Friday, November 15th. Four equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the stock. Diplomat Pharmacy has a consensus rating of “Hold” and an average price target of $7.88.
A number of institutional investors and hedge funds have recently made changes to their positions in DPLO. Royal Bank of Canada boosted its stake in Diplomat Pharmacy by 184.8% in the second quarter. Royal Bank of Canada now owns 4,782 shares of the company’s stock valued at $29,000 after acquiring an additional 3,103 shares in the last quarter. Man Group plc acquired a new stake in shares of Diplomat Pharmacy during the third quarter worth $51,000. Bank of Montreal Can lifted its stake in shares of Diplomat Pharmacy by 138.4% during the second quarter. Bank of Montreal Can now owns 11,444 shares of the company’s stock worth $70,000 after buying an additional 6,644 shares during the period. Ladenburg Thalmann Financial Services Inc. acquired a new stake in shares of Diplomat Pharmacy during the second quarter worth $77,000. Finally, Metropolitan Life Insurance Co NY lifted its stake in shares of Diplomat Pharmacy by 17.5% during the third quarter. Metropolitan Life Insurance Co NY now owns 18,906 shares of the company’s stock worth $93,000 after buying an additional 2,820 shares during the period. Institutional investors own 84.14% of the company’s stock.
Shares of NYSE DPLO traded down $0.02 during midday trading on Friday, reaching $3.98. 501,319 shares of the company’s stock traded hands, compared to its average volume of 1,234,549. The company has a quick ratio of 0.36, a current ratio of 0.55 and a debt-to-equity ratio of 0.18. The stock’s 50 day simple moving average is $4.26 and its 200-day simple moving average is $5.05. Diplomat Pharmacy has a one year low of $2.43 and a one year high of $14.53. The company has a market cap of $304.00 million, a price-to-earnings ratio of -0.46 and a beta of 0.86.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Featured Article: Inverted Yield Curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.